Cidara Therapeutics, Inc. — Director's Dealing 2021

Aug 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cidara Therapeutics, Inc. (CDTX)
CIK: 0001610618
Period of Report: 2021-08-18

Reporting Person: Stein Jeffrey (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-18	Common Stock	P	40000	$1.7221	Acquired	405878	Direct
2021-08-19	Common Stock	P	10000	$1.7871	Acquired	415878	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	231602	Indirect
Common Stock	42009	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6990 to $1.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2021.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7850 to $1.7899, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set
forth above.